Journal of Clinical Psychiatry

Journal

Publication Venue For

  • Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.  80. 2019
  • A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).  80. 2019
  • Efficacy of ziprasidone augmentation of escitalopram for cognitive symptoms of major depressive disorder.  79:55-59. 2018
  • Clinical and genetic predictors of delayed remission after multiple levels of antidepressant treatment: Toward early identification of depressed individuals for advanced care options.  78:e1291-e1298. 2017
  • Ziprasidone augmentation of escitalopram for major depressive disorder: Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study.  78:449-455. 2017
  • Long-Term Efficacy, Safety, and Tolerability of l-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors: A 12-Month, Open-Label Study Following a Placebo-Controlled Acute Study.  77:654-660. 2016
  • Baseline disability and poor functioning in Bipolar disorder predict worse outcomes: Results from the Bipolar CHOICE study.  77:100-108. 2016
  • Bipolar CHOICE (clinical health outcomes initiative in comparative effectiveness): A pragmatic 6-month trial of lithium versus quetiapine for Bipolar disorder.  77:90-99. 2016
  • Association of obesity and inflammatory marker levels on treatment outcome: Results from a double-blind, randomized study of adjunctive l-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.  76:1635-1641. 2015
  • MDDScore: Confirmation of a blood test to aid in the diagnosis of major depressive disorder.  76:e199-e206. 2015
  • Reply to commentary by rothschild: "A blood test for depression?".  76:e1038. 2015
  • What are the comparative benefits and harms of augmentation treatments in major depression?.  76:e531-e533. 2015
  • A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.  73:1541-1547. 2012
  • Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression..  72. 2011
  • Challenges and algorithm-guided treatment in major depressive disorder..  72. 2011
  • Crisis of confidence: antidepressant risk versus benefit..  72. 2011
  • A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.  72:1405-1412. 2011
  • Evidence for the use of l-methylfolate combined with antidepressants in MDD..  72. 2011
  • Moderators of antidepressant response in major depression..  72. 2011
  • Performance improvement CME: algorithms and EMRs in depression..  72. 2011
  • Using algorithms and computerized decision support systems to treat major depression..  72. 2011
  • St John's wort (Hypericum perforatum) in major depression.  70:23-27. 2009
  • Long-term management of depression: Tips for adjusting the treatment plan as the patient's needs change.  70:32-37. 2009
  • Family history of depression and therapeutic outcome: Findings from STAR*D.  70:185-195. 2009
  • Pathophysiologic mechanisms of fibromyalgia and its related disorders.  69:6-13. 2008
  • Do Atypical Antipsychotics Effectively Treat Co-Occurring Bipolar Disorder and Stimulant Dependence?.  69:1257-1266. 2008
  • Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial.  69:1257-1266. 2008
  • Evaluating and diagnosing fibromyalgia and comorbid psychiatric disorders..  69. 2008
  • Multidisciplinary care and stepwise treatment for fibromyalgia..  69. 2008
  • The history and current state of antidepressant clinical trial design: A call to action for proof-of-concept studies.  69:1513-1528. 2008
  • Augmentation strategies to increase antidepressant efficacy.  68:18-22. 2007
  • Dr. Shelton replies [4].  68:1619. 2007
  • The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: Outcomes from the 2-year and combined maintenance phases.  68:1246-1256. 2007
  • Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study.  68:1071-1077. 2007
  • A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.  68:1546-1551. 2007
  • Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort.  68:1931-1938. 2007
  • Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis.  68:826-831. 2007
  • Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study.  68:1014-1023. 2007
  • Use of treatment algorithms for depression.  67:1458-1465. 2006
  • Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research.  67:27-30. 2006
  • The nature of the discontinuation syndrome associated with antidepressant drugs.  67:3-7. 2006
  • A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.  67:1674-1681. 2006
  • Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance.  66:1289-1297. 2005
  • Psychiatric genetics: A survey of psychiatrists' knowledge, opinions, and practice patterns.  66:821-830. 2005
  • Risperidone and paroxetine given singly and in combination for bipolar depression.  65:1715-1719. 2004
  • The dual-action hypothesis: Does pharmacology matter?.  65:5-10. 2004
  • The effectiveness of St. John's wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication.  65:1114-1119. 2004
  • Risperidone in the treatment of delirium: Results from a prospective open-label trial.  65:662-667. 2004
  • The use of antidepressants in novel combination therapies.  64:14-18. 2003
  • Mechanisms of action in the treatment of anxiety.  62:10-15. 2001
  • Introduction: Remission of anxiety-related disorders.  62:3-4. 2001
  • Measuring patient symptom change on rural psychiatry units: Utility of the symptom checklist-90 revised.  61:493-497. 2000
  • Mood-stabilizing drugs in depression.  60:37-42. 1999
  • Treatment options for refractory depression.  60:57-63. 1999
  • The distribution of body mass index among individuals with and without schizophrenia.  60:215-220. 1999
  • Update on the management of bipolar illness.  59:484-495. 1998
  • The undertreatment of dysthymia.  58:59-65. 1997
  • Fluoxetine in dementia of the Alzheimer's type: Prominent adverse effects and failure to improve cognition [1].  55:161. 1994
  • The effects of race and comorbidity on clinical diagnosis in patients with psychosis.  54:96-102. 1993
  • International Standard Serial Number (issn)

  • 0160-6689
  • Electronic International Standard Serial Number (eissn)

  • 1555-2101